AN2 Therapeutics, Inc.

NasdaqGS ANTX

AN2 Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -60.70 M

AN2 Therapeutics, Inc. Net Income is USD -60.70 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -1.32% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

AN2 Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -59.91 M, a -67.65% change year over year.
AN2 Therapeutics, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -35.73 M.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqGS: ANTX

AN2 Therapeutics, Inc.

CEO	Mr. Eric E. Easom
IPO Date	March 25, 2022
Location	United States
Headquarters	1800 El Camino Real
Employees	41
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Key trends

Past 5 years